Skip to content
Home/Companies/Pharma/Symbio
SY

Symbio

Pharma·US·Active·3yr hold

Symbio is a TMT company, headquartered in France.

Entry
2023
Hold
3yr
Status
Active
Est. EV
–

Who owns Symbio?

Symbio is currently owned by ARCHIMED through MED Platform II (2022 vintage), since 2023. Across its history, Symbio has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-04-21

ARCHIMED
Most recent investor
ARCHIMED
MED Platform II · 2022 · Buyout
2 ownership periods · full history below

Key facts

HQFrance
SectorTMT

Ownership history

2 ownership periods

Active
Currently held by ARCHIMED since 2023.
ENGIE New Ventures
ENGIE New VenturesExited 2019
2016 · 2019 · ENGIE New Ventures Fund · 2014 · VC
Trade Sale · to
MOIC
–
ARCHIMED
ARCHIMEDActive
2023 · present · MED Platform II · 2022 · Buyout
MOIC
–

More from MED Platform II

Other portfolio companies in the same fund.

ARK Diagnostics
Active
MedTechUS· 2025
Instem
Active
HealthTechUS· 2023
WiQo
Active
HealthTechItaly· 2023
Corealis
Active
PharmaCanada· 2022
Natus
Active
MedTechUS· 2022

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Delpharm
Active
SocadifFrance
Laboratoires Delbert
Active
SocadifFrance
Biogaran
Active
BC PartnersFrance· 2025
Dec Group
Active
capitonSwitzerland· 2025
Essential Pharma
Active
Penta CapitalUK· 2025
Forth Therapeutics
Active
Old College CapitalUK· 2025
Data refreshed weekly · Sourced from public filings